{"authors": [["Tran", "Thao T", "TT", "US Food and Drug Administration, 10903 New Hampshire AvenueBldg 22 Silver Spring Maryland, United States."], ["Brinker", "Allen D", "AD", "US Food and Drug Administration, 10903 New Hampshire AvenueBldg 22 Silver Spring Maryland, United States."], ["Mu\u00f1oz", "Monica", "M", "US Food and Drug Administration, 10903 New Hampshire AvenueBldg 22 Silver Spring Maryland, United States."]], "text": "Several endothelin receptor antagonists (ERAs) that were developed for the treatment of pulmonary arterial hypertension (PAH), including bosentan and sitaxentan, have been linked to clinically significant hepatocellular injury, as well as liver failure. We describe the first case of fulminant hepatitis to be reported in association with the ERA macitentan. This case was recently identified within the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and and describes liver transplantation occuring 13 months following macitentan initiation in a young patient (23-years old) with idiopathic PAH New York Heart Association (NYHA) functional class III. This article is protected by copyright. All rights reserved.", "id": "29286546", "date": "2017-12-29", "title": "Serious Liver Injury Associated with Macitentan: A Case Report.", "doi": "10.1002/phar.2078", "journal": ["Pharmacotherapy", "Pharmacotherapy"]}